Renaissance Capital logo

AARD News

LB Pharmaceuticals prepares to break the biotech IPO dry spell

Aardvark Therapeutics logo

Neuropsych biotech LB Pharmaceuticals (LBRX) filed for a $100 million IPO on Friday, marking the first major new filing from a drug developer since January. Backed by a suite of VCs, LB Pharmaceuticals is initially developing its lead candidate, oral small...read more

Renaissance Capital's February IPO Market Update

Aardvark Therapeutics logo

Eighteen IPOs raised a combined $2.8 billion in February, well above the 10-year historical average (12 IPOs, $2.1B). Micro-caps dominated deal flow, but five issuers completed offerings of $100 million or more, led by SailPoint (SAIL), which raised $1.4...read more

Bigger Biotechs: IPO valuations have soared for drug developers over the past decade

Aardvark Therapeutics logo

New biotech issuers have doubled in size over the past decade. Last year, the average biotech IPO went public at a market cap of $644 million, compared to $318 million a decade earlier, for deals raising at least $20 million. The average wasn’t skewed by ...read more

US IPO Weekly Recap: Big listings post mixed results in busy 7 IPO week

SAIL

Seven IPOs and three SPACs listed this week. Seven IPOs and four SPACs submitted initial filings. Identity governance software provider SailPoint (SAIL) priced it upsized IPO at the top of the upwardly revised range to raise $1.4 billion at a $13.2 billion...read more